The 12 Most Common Questions about LASIK
1. What Are the Risks?
2. Are Contacts Safer Than LASIK?
3. Can I Really Get Rid of My Glasses?
4. Will LASIK Work for Me?
5. Will It Hurt?
6. When Can I Return to Work?
7. Aren’t All Bladeless LASIK Procedures the Same?
8. What If I Blink or Move During the Procedure?
9. What About Nighttime Side-Effects?
10. Does the Type of Technology Matter?
11. Should I Wait for the Cost to Come Down?
12. How do I Choose the Best Doctor?
1. What Are the Risks?
The American Academy of Ophthalmology has declared LASIK safe and effective for most people. More than 12,500,000 Americans have had LASIK since 1996 with the surgeons having reported a less than a 2% complication rate. Those complications were mostly related to quality of vision issues such as dry eyes and reduced night vision – not loss of vision – and even these have been significantly reduced by advances in laser technology.
In reality, there is more risk from ignoring the simple post-operative medication directions than something going wrong during the procedure; however, receiving a proper consultation to confirm you’re a proper candidate in the first place is the best assurance that you will have a successful outcome. (top)
2. Are Contacts Safer Than LASIK?
Both are considered safe, although some studies have reported increased risk of infection from contacts due to prolonged wear and poor maintenance, such as forgetting to take them out when you sleep. The main reason contacts cause problems is because of the hassle factor. Forget your cleaning solutions, overlook the need to sterilize them, have them slip while you’re driving, and the risk increases.(top)
LASIK, on the other hand, is a precision, permanent, no-maintenance solution to poor vision due to refractive error, and as Dr. William Mathers at the Oregon Health & Science University reported: “One shouldn’t just assume that contacts are safer than LASIK. This may have been true at one time, but for the average person this is certainly not the case anymore.”(top)
3. Can I Really Get Rid of My Glasses?
If you are between the ages of 18 and 45 most do not need prescription glasses after LASIK. After the age of approximately 45, a different vision condition comes into play: presbyopia. Presbyopia is a natural result of aging and most of us will likely need reading glasses whether we have had LASIK or not. Even presbyopia can be effectively handled through a special LASIK technique known as monovision which has given thousands the ability to see both close up and far away.(top)
4. Will LASIK Work for Me?
This is the BIG question – and it can only be fully answered by having a comprehensive LASIK Consultation.
Most people over age 18 who suffer from nearsightedness, farsightedness or astigmatism can be helped with LASIK. Particular physical or medical factors such as corneal thickness or forms of diabetes may rule someone out as a LASIK candidate. But the only way to know for sure if LASIK is the answer to your poor vision is by having a full and comprehensive LASIK consultation with a reputable doctor.(top)
5. Will It Hurt?
LASIK in the hands of an experienced surgeon is virtually painless.
You can expect a sensation of pressure during the procedure. Inserting or removing contact lenses, or just rubbing tired eyes from wearing glasses can produce more discomfort than an all-laser LASIK procedure. After a good night’s sleep you can expect to awaken to the joy of seeing the world clearly and without lenses – usually for the first time in many years – and without the discomfort and irritations of lenses.(top)
6. When Can I Return to Work?
Most people are able to return to work within 24-48 hours of their LASIK procedure.
Immediately after the procedure you’ll be asked to go home and take a nap so the healing process can get off to a good start. You’ll also be prescribed eye drops to assist in the healing process.(top)
7. Aren’t All Bladeless LASIK Procedures the Same?
All-laser or blade-free LASIK involves the use of two separate lasers. The first is the femtosecond laser and is used to create the protective corneal flap. The second is the excimer laser which is used specifically to reshape the corneal tissue. These refractive correction procedures should only be performed by an ophthalmologic surgeon, however in some states general optometrists are permitted to perform a procedure known as Photorefractive Keratectomy or PRK, and sometimes refer to this as “bladeless LASIK” – a very misleading statement.
PRK is a less comfortable procedure than LASIK and involves the use of a chemical solvent to remove the protective outer layers of the cornea, rather than using a laser to create a corneal flap. As a result, the eye can take up to two months to achieve the level of vision that LASIK can deliver in just a day or two. PRK is occasionally necessary for some eye conditions where the cornea is too thin to create a protective flap, but on average, only around 5% of patients will require it.(top)
8. What If I Blink or Move During the Procedure?
Sometimes patients worry that they will affect the surgery by nervous or uncontrollable twitches or jumps of their eyes, called saccadic eye movements. The lasers used in LASIK are married to an ultra high speed eye tracking system with a response time of milliseconds – much faster than your eye can move. This eye tracker completely compensates for these eye movements and turns the laser off instantly the moment the eye is out of the treatment zone.(top)
9. What About Nighttime Side-Effects?
Most of us have night vision issues whether we have had LASIK or not. However, you may have seen news stories about people having difficulty driving at night after refractive surgery. Nighttime side-effects are rare and may include halos, starbursts, and glare around lights and blurry vision. These effects, if they occur, usually diminish as the eye heals in the first three months. In extreme cases additional touch-up (enhancement) procedures might be recommended.
However, today’s advanced technology in the hands of an experienced surgeon has almost completely eliminated this minor and temporary side-effect. In fact, many patients now report improved night vision after LASIK.(top)
10. Does the Type of Technology Matter?
Yes it does – but less so than the personal track record and expertise of the surgeon performing your procedure. Newer technology solves issues that older technology couldn’t address and one of the greatest changes due to ongoing technological breakthroughs has been an increase in the number of patients who can now be successfully treated with LASIK.
But the best assurance of a successful outcome is by choosing a doctor who has an excellent personal track record, a local reputation for excellence, and who takes a personal interest in each patient at every step of the way.(top)
11. Should I Wait for the Cost to Come Down?
Unfortunately, the cost of LASIK has been rising since the 90s and is likely to keep on rising.
The costs of today’s highly advanced technology is one factor and LASIK is most definitely a hands-on, personalized service requiring highly trained surgeons and staff. The few minutes of the procedure are the tip of the iceberg compared to the behind-the-scenes involvement of technical personnel, their training, facilities and procedures for patient care, and the programming and maintenance of the computers.
Although some centers quote attractively (and misleadingly) low prices, the truth is that, as with anything in life, “you get what you pay for” and the improved vision that you will enjoy for many decades to come does come at a price.(top)
The good news is that the onetime cost of a high-quality LASIK procedure can be very affordable once low-interest payment options are factored into the decision.
12. How do I Choose the Best Doctor?
This is definitely the most important question of all once you’ve decided to consider LASIK. Although LASIK is sometimes marketed as a commodity, it is a medical procedure. In the final analysis, the skill and care of the surgeon are the most significant issues.
Look for a LASIK center that is owned by the surgeon. This will show the level of commitment he/she has to their patients and will best allow you to make a decision about their qualifications, rather than a corporately owned center where the numbers being quoted are for doctors who show up simply to perform the surgery.
Ensure you feel at ease with the surgeon and his/her staff and that you’re being treated with the respect and care that you deserve as an individual.
Don’t accept excuses or discouragement on this point or be misled by low prices offered – they’re usually not genuine. Remember, the only ‘dumb’ question is the one you don’t ask.(top)
IMPORTANT SAFETY INFORMATION
IntraLase
Indications for Use
The IntraLase FS and iFS Lasers are 21 CFR 1040 class IIIb ophthalmic surgical lasers with the following indications for use:
- In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea
- In patients undergoing surgery or other treatment requiring initial lamellar resection of the cornea to create tunnels for placement of corneal ring segments
- In lamellar keratoplasty and corneal harvesting
- In keratomileusis in situ for the correction of myopia
- In the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring initial lamellar resection of the cornea
- In the creation of a lamellar cut/resection of the cornea for lamellar keratoplasty and for the creation of a penetrating cut/incision for penetrating keratoplasty.
The IntraLase FS and iFS Laser delivery systems are used in conjunction with a sterile disposable IntraLase Patient Interface, consisting of pre-sterilized suction ring assemblies and pre-sterilized applanation lenses, intended for single-use.
The IntraLase FS and iFS Lasers should only be operated by, or under the direct supervision of a trained physician with certification in laser safety and in the use of the IntraLase FS Laser.
Flap Contraindications
Lamellar resection for the creation of a corneal flap using the IntraLase FS or iFS Lasers is contraindicated if any of the following conditions exist. Potential contraindications are not limited to those included in this list:
- Corneal edema
- Corneal lesions
- Hypotony
- Glaucoma
- Existing corneal implant
- Keratoconus
IntraLase Enabled Keratoplasty (IEK) Contraindications
Contraindications to use of the IntraLase FS or iFS Lasers for the indications described for the IEK procedure include:
- Any corneal opacity adequately dense to obscure visualization of the iris;
- Descemetocoele with impending corneal rupture;
- Previous corneal incisions that might provide a potential space into which the gas produced by the procedure can escape; and
- Corneal thickness requirements that are beyond the range of the system.
The following conditions should also be considered when using the IntraLase FS or iFS Lasers for IEK:
- Severe corneal thinning
- Subjects with pre-existing glaucoma
- A history of steroid responsive rise in intraocular pressure
- Preoperative intraocular pressure greater than 21 mmHg in the operative eye
- Subjects with more than 1200 µm corneal thickness at the 9 mm peripheral zone
- Active intraocular inflammation
- Active ocular infection
Warnings
FS and iFS Lasers
- The performance of surgical or laser alignment procedures, operation of controls or any other adjustments other than those specified herein may result in hazardous conditions for both patients and personnel.
- While the risk of fire is extremely low, the IntraLase FS or iFS Laser should not be operated in the presence of flammable anesthetics, volatile substances, or oxygen flow lines.
- Only certified accessories that conform to National and International standards (i.e., IEC 60950-1, IEC 60601-1 or similar) should be connected to the input/output ports on the FS Laser.
- High voltage electrical circuits are accessible if the console panels are removed. Only trained AMO service representatives should attempt to open the console panels. Serious injury or death may occur as a result of exposure to electrical circuits in the unit interior.
- Do not use cell phones, pagers, or radio frequency devices of any kind in the same room as the IntraLase FS or iFS Laser.
- If an articulating chair is used in conjunction with the FS or iFS Laser system, take proper precautions to avoid any unintended movement of the chair toward the laser system. Refer to the specific operating instructions provided by the manufacturer of the articulating chair.
- To ensure the proper operation of the Z-Verifier safety features, use the joystick to applanate and to activate the green eye contact LED. Do not lift and place the objective on the eye in lieu of using the joystick.
- The suction ring assembly must be disengaged from the patient's cornea before using the Home button.
- Check all treatment parameters for accuracy.
- Only trained AMO service representatives should perform unpacking, installation, and servicing of the IntraLase FS or iFS Lasers. Covers must not be removed by anyone other than AMO service representatives. Accidental contact with the high voltage electrical circuits in the interior of the IntraLase FS or iFS Laser consoles may result in serious injury or death.
- Ocular exposure to collimated beams contained in the console interior can produce retinal damage.
- The UPS (Uninterruptable Power Supply) is designed for exclusive use with the FS or iFS Laser system. Do not connect any other electrical device to the UPS system.
- Check all parameters for accuracy before proceeding to the next phase.
- Patient procedures performed with an improperly operating IntraLase FS or iFS Laser may produce poor or otherwise unacceptable resections, or may result in complications.
- Use of this laser system allows laser surgical incisions to be created up to 1200 µm deep. Additionally, resection patterns can be freely adjusted to create various geometric shapes. It is advised that the user check all treatment parameters, and then verify the pattern outline in the graphical display, before proceeding to the next phase.
- Setting the posterior depth too deep during could result in injury to other intraocular structures.
- Operation of this system, with the keratoplasty application, requires that the user provide a calibrated corneal thickness measurement device.
- Caution must be taken to remove suction prior to removing applanation to avoid injury to intraocular structures.
Patient Interface
- The Patient Interface disposables should not be reused or re-sterilized.
- Used IntraLase Patient Interface assemblies should be treated as medical waste. Use and disposal of the IntraLase Patient Interface is detailed in the IntraLase Patient Interface Directions for Use (DFU).
- The applanation lens becomes etched by the laser during the side-cut procedure and MUST NOT be re-used. Laser light will not effectively permeate an etched lens, and the precision of the laser will be altered.
- To preserve sterility, open the disposable tray while wearing sterile, powder free surgical gloves and complete the following steps.
- Do not attempt to use a damaged Patient Interface.
- If the suction ring assembly clip fails to disengage, or if it prematurely disengages, do not attempt use.
Flap Complications
Possible complications resulting from Lasik surgery include (potential complications are not limited to those included in this list):
- Corneal edema
- Corneal pain
- Epithelial ingrowth
- Epithelial defect
- Infection
- Flap de-centration
- Incomplete flap creation
- Flap tearing or incomplete lift-off
- Free cap
- Photophobia
- Corneal inflammation, such as diffuse lamellar keratitis (DLK), corneal infiltrates, and iritis
- Thin or thick flaps
- Flap striae
The following sporadically reported visual symptoms may occur following LASIK flap creation with the IntraLase FS or iFS Laser.
Transient Light Sensitivity Syndrome (TLSS)
Transient Light Sensitivity Syndrome is characterized by symptoms of mild to severe light sensitivity which manifests between two and six weeks postoperatively. Patients experience no decrease in uncorrected or best spectacle-corrected visual acuity. The incidence of this sensitivity is observed in approximately 1% of patients who undergo flap creation with the IntraLase FS laser. Patients respond to the use of hourly topical steroids such as Pred Forte, and most report improvement within one week of treatment.
Peripheral Light Spectrum (PLS)
Peripheral Light Spectrum (PLS) is a temporary phenomenon whereby patients report the perception of a spoke-like spectrum of light in the periphery of their vision. PLS has no clinical examination findings and no effect on visual acuity; however the potential diffractive effects may be bothersome to some patients. Reported in only 0.03% of cases, the onset of symptoms occurs during the immediate postoperative period, and typically resolves within three months but may be slightly persistent in rare cases. The visual impact of PLS is clinically inconsequential for the vast majority of patients.
US Federal law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed eye care practitioner.
VISX S4 IR
VISX Wavefront-Guided LASIK for Correction of Myopic Astigmatism, Hyperopic Astigmatism and Mixed Astigmatism (CustomVue LASIK Laser Treatment)
Statements regarding the potential benefits of wavefront-guided LASIK (CustomVue) are based upon the results of clinical trials. These results are indicative of not only the CustomVue treatment but also the care of the clinical physicians, the control of the surgical environment by those physicians, the clinical trials' treatment parameters and the clinical trials' patient inclusion and exclusion criteria. Although many clinical trial patients after the CustomVue Procedure saw 20/20 or better and/or had or reported having better vision during the day and at night, compared to their vision with glasses or contact lenses before the procedure, your results may vary. You can find information about the clinical trials below and in the CustomVue Patient Information Booklet. Only an eye care professional trained in laser vision correction can determine whether you are a suitable candidate for the CustomVue Procedure. As with any surgical procedure, there are risks associated with the CustomVue treatment. Before deciding whether to have the CustomVue Procedure, you should ask your doctor for and carefully review the CustomVue Patient Information Booklet. It is important to discuss the risks associated with the procedure and any questions you may have about the procedure with your doctor.
WAVEFRONT-GUIDED LASIK INDICATIONS AND INTENDED USES (LOW TO MODERATE MYOPIC ASTIGMATISM):
The VISX STAR S4 Excimer Laser System and WaveScan WaveFront System is approved to perform wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of low to moderate myopic astigmatism up to -6.00 D MRSE, with cylinder between 0.00 and -3.00 D in patients 21 years of age or older; and in patients with documented evidence of a change in manifest refraction of no more than 0.50 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is "STAR S4 ActiveTrak Excimer Laser System for wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments of myopic astigmatism up to -6.00 D MRSE, with cylinder between 0.00 and -3.00 D." An acceptable alternate version of this official name is "wavefront-guided LASIK for correction of myopic astigmatism."
Wavefront-guided LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application is based on a clinical trial of 351 eyes (189 primary and 162 secondary). Of all eyes treated, 318 were evaluated for effectiveness with 98.8% accountability at 3 months, 277 eyes with 96.9% accountability at 6 months, 102 eyes with 95.3% accountability at 9 months, and 86 eyes with 95.6% accountability at 12 months. The studies found that of the 277 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 100% were corrected to 20/40 or better, and 95.8% were corrected to 20/20 or better in 71 spherical myopia eyes; and 99.5% were corrected to 20/40 or better, and 93.2% were corrected to 20/20 or better in 206 astigmatic myopia eyes.
The study showed that at the 3 month stability time point: there was a loss of ?2 lines of best corrected vision that can be obtained with spectacles in 1 of 239 astigmatic myopia eyes and there was no loss of ?2 lines of best corrected vision in 79 spherical myopia eyes; there was 1 of 239 astigmatic myopia eyes with best spectacle corrected visual acuity (BSCVA) worse than 20/25 and none in 79 spherical myopia eyes with BSCVA worse than 20/25. During the course of study, no eye lost >2 lines of BSCVA and no eye had a BSCVA worse than 20/40.
WAVEFRONT-GUIDED LASIK INDICATIONS AND INTENDED USES (HIGH MYOPIC ASTIGMATISM):
The VISX STAR S4 IR Excimer Laser System with VSS and WaveScan WaveFront System are approved to perform wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of high myopic astigmatism from -6.00 D to -11.00 D MRSE, with cylinder between 0.00 and -3.00 D in patients 21 years of age or older; and in patients with documented evidence of a change in manifest refraction of no more than 1.00 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is "STAR S4 IR Excimer Laser System for wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments of myopic astigmatism from -6.00 to -11.00 D MRSE, with cylinder between 0.00 and -3.00 D." An acceptable alternate version of this official name is "wavefront-guided LASIK for correction of high myopia with or without astigmatism."
Wavefront-guided LASIK for correction of high myopic astigmatism is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application is based on a clinical trial of 184 eyes. Of all eyes treated, 180 were evaluated for effectiveness with 97.8% accountability at 3 months, 178 eyes with 96.7% accountability at 6 months, 170 eyes with 96.5% accountability at 9 months, and 107 eyes with 93.9% accountability at 12 months. The studies found that of the 178 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 98.3% were corrected to 20/40 or better, 97.2% were corrected to 20/32 or better, and 84.3% were corrected to 20/20 or better without spectacles or contact lenses. The study showed that of 83 spherical and 101 astigmatic eyes, no eyes lost 2 or more lines of best corrected vision that can be obtained with spectacles (BSCVA) and none of the eyes had BSCVA worse than 20/40.
WAVEFRONT-GUIDED LASIK INDICATIONS AND INTENDED USES (HYPEROPIC ASTIGMATISM):
The VISX STAR S4 Excimer Laser System and WaveScan WaveFront System are approved to perform wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of hyperopic astigmatism up to +3.00 D MRSE, with cylinder between 0.00 and +2.00 D in patients 21 years of age or older; and in patients with documented evidence of a change in manifest refraction of no more than 1.0 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is "STAR S4 ActiveTrak Excimer Laser System for wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments of hyperopic astigmatism up to +3.00 D MRSE, with cylinder between 0.00 and +2.00 D." An acceptable alternate version of this official name is "wavefront-guided LASIK for correction of hyperopic astigmatism."
Wavefront-guided LASIK for hyperopic astigmatism is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application was based on a clinical trial of 144 eyes (74 primary and 70 secondary). Of all eyes treated, 134 were evaluated for effectiveness with 98.5% accountability at 3 months, 131 eyes with 97.0% accountability at 6 months, 118 eyes with 90.8% accountability at 9 months, and 27 eyes with 87.1% accountability at 12 months. The studies found that of the 131 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 97.3% were corrected to 20/40 or better, and 66.2% were corrected to 20/20 or better in 74 spherical hyperopia eyes; and 93.0% were corrected to 20/40 or better, and 56.1% were corrected to 20/20 or better in 57 astigmatic hyperopia eyes.
The study showed that at the 6 month stability time point: there was no loss of ?2 lines of best corrected vision that can be obtained with spectacles in 1 of 239 astigmatic myopia eyes and there was no loss of ?2 lines of best corrected vision that can be obtained with spectacles in either 63 astigmatic hyperopia eyes or 74 spherical hyperopia eyes; none of the 63 astigmatic hyperopia or 74 spherical hyperopia eyes had best spectacle corrected visual acuity (BSCVA) worse than 20/25. During the course of the study, one in 63 eyes with astigmatic hyperopia lost >2 lines of BSCVA at 1 month, no eyes with spherical hyperopia lost >2 lines of BSCVA, and no eye had a BSCVA worse than 20/40.
WAVEFRONT-GUIDED INDICATIONS AND INTENDED USES (MIXED ASTIGMATISM):
The VISX STAR S4 IR Excimer Laser System with VSS and WaveScan WaveFront System are approved to perform wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of naturally occurring mixed astigmatism when the magnitude of cylinder (from 1.0 to 5.0 D) is greater than the magnitude of sphere and the cylinder and sphere have opposite signs; and in patients 21 years of age or older with documented evidence of a change in manifest refraction of no more than 0.50 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is "STAR S4 IR Excimer Laser System" for wavefront-guided laser assisted in-situ keratomileusis (LASIK) treatments of naturally occurring mixed astigmatism when the magnitude of cylinder (from 1.0 to 5.0 D) is greater than the magnitude of sphere and the cylinder and sphere have opposite signs. An acceptable alternate version of this official name is "wavefront-guided LASIK for correction of mixed astigmatism."
Wavefront-guided LASIK for mixed astigmatism is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application is based on a clinical trial of 86 eyes. Of all eyes treated, 86 were evaluated for effectiveness with 100.0% accountability at 3 months, 80 eyes with 95.2% accountability at 6 months, 69 eyes with 86.3% accountability at 9 months, and 63 eyes with 94.0% accountability at 12 months. The studies found that of the 86 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 3 months, 95.3% were corrected to 20/40 or better, 91.9% were corrected to 20/32 or better, and 61.6% were corrected to 20/20 or better without spectacles or contact lenses.
The study showed that of 86 astigmatic eyes, one eye temporarily lost 2 lines of best corrected vision that can be obtained with spectacles at 1 month and at 6 months, and none of the eyes had best spectacle corrected visual acuity (BSCVA) worse than 20/40.
CONTRAINDICATIONS:
Wavefront-guided LASIK is contraindicated in patients with collagen vascular, autoimmune or immunodeficiency disease, signs of keratoconus or abnormal corneal topography, patients taking isotretinoin (Accutane®*) or amiodarone hydrochloride (Cordarone®†) or are pregnant or nursing.
WARNINGS:
Wavefront-guided LASIK is not recommended in patients who have diabetes, a history of Herpes simplex or Herpes zoster keratitis, significant dry eye that is unresponsive to treatment, or severe allergies. For the treatment of low to moderate myopic astigmatism, lower uncorrected visual acuity may be anticipated in the treatment of higher degrees of myopia with and without astigmatism (?5.0 D MRSE).
PRECAUTIONS:
Long-term risks of wavefront-guided LASIK beyond 12 months have not been studied. The safety and effectiveness of wavefront-guided LASIK surgery has ONLY been established with an optical zone of 6 mm and an ablation zone of 8 mm for myopic treatments, and an ablation zone of 9 mm for hyperopic and mixed astigmatism treatments. The safety and effectiveness of STAR S4 Excimer Laser System have NOT been established for wavefront-guided surgery in patients with low to moderate myopic astigmatism: whose WaveScan wavefront diameter is less than 6 mm; for treatments greater than -6 diopters of MRSE or with greater than 3 diopters of astigmatism and for retreatment with CustomVue LASIK. The safety and effectiveness of STAR S4 Excimer Laser System have NOT been established for wavefront-guided surgery in patients with high myopic astigmatism: whose WaveScan wavefront diameter is less than 5 mm; for treatments greater than -11 diopters of MRSE or with greater than 3 diopters of astigmatism. The safety and effectiveness of STAR S4 Excimer Laser System have NOT been established for wavefront-guided surgery in patients with hyperopic astigmatism: whose WaveScan wavefront diameter is less than 5 mm; for treatments greater than +3 diopters of MRSE or with greater than 2 diopters of astigmatism and for retreatment with CustomVue LASIK. The safety and effectiveness of the STAR S4 IR Excimer Laser System have NOT been established for wavefront-guided surgery in patients with mixed astigmatism: whose WaveScan wavefront diameter is less than 5.00 mm; for treatments greater than 5.00 D or less than 1.00 D of astigmatism and for retreatment with CustomVue LASIK.
Although the WaveScan WaveFront System measures the refractive error and wavefront aberrations of the human eyes, including myopia, hyperopia, astigmatism, coma, spherical aberration, trefoil, and other higher order aberrations through sixth order, in the clinical studies for low to moderate myopic astigmatism, hyperopic astigmatism and mixed astigmatism, the average higher order aberration did not decrease after CustomVue treatment. In the clinical studies for high myopic astigmatism, the average higher order aberration increased after CustomVue treatment.
It is possible, after wavefront-guided LASIK treatment, that patients will find it more difficult than usual to see in conditions such as very dim light, rain, snow, fog, or glare from bright lights at night. Visual performance possibly could be worsened by large pupil sizes or decentered pupils. Pupil size should be evaluated under mesopic illumination conditions.
ADVERSE EVENTS AND COMPLICATIONS (LOW TO MODERATE MYOPIC ASTIGMATISM):
The clinical trial showed that the following adverse events or complications occurred in at least 1% of the 351 eyes at any interval up to 6 months post-treatment: inflammation of the cornea under the flap (1.4%); double or ghost images (1.4%); and scratch on the surface of the eye (1.4%).
The following subjective symptoms frequency rated "often or always" were increased in the effectiveness cohort at 6 months post-treatment on 258 eyes compared with pre-treatment on 332 eyes: dryness (9% vs. 6%); fluctuation of vision (3% vs. 2%); glare (4% vs. 2%) and halos (7% vs. 5%).
ADVERSE EVENTS AND COMPLICATIONS (HIGH MYOPIC ASTIGMATISM):
The clinical trial showed that the following adverse events or complications occurred in at least 1% of the 184 eyes at one or more postoperative examinations up to 6 months post-treatment: cells growing under the flap (1.1%); scratch on the surface of the eye at 1 month or later (2.2%); swelling of the corneal between 1 week and 1 month postoperatively (2.7%) and double vision (or "ghost images") in the operative eye (6.0%).
The following subjective symptoms were reported as present "often or always" by a higher percentage of subjects 6 months after treatment than before treatment: dryness (10.8% vs. 9.3%); halos (21.6% vs. 15.4%); and ghosting or shadowing of images (2.8% vs. 1.1%).
ADVERSE EVENTS AND COMPLICATIONS (HYPEROPIC ASTIGMATISM):
The clinical trial showed that the following adverse events or complications occurred in at least 1% of the 144 eyes at any interval up to 6 months post-treatment: cells growing under the flap (2.1%); feeling of something in the eye (1.4%); double or ghost images (11.3%); and scratch on the surface of the eye (2.1%).
The following subjective symptoms rated "often or always" were increased in frequency in the effectiveness cohort at 6 months post-treatment on 131 eyes compared with pretreatment on 136 eyes: dryness (17% vs. 6%); blurry vision (10% vs. 7%); fluctuation of vision (14% vs. 6%); halos (10% vs. 5%); double or ghost images (7% vs.3%).
ADVERSE EVENTS AND COMPLICATIONS (MIXED ASTIGMATISM):
The clinical trials showed that the following adverse events or complications occurred in at least 1% of the 86 eyes at one or more postoperative examinations up to 3 months post-treatment: miscreated flap (1.2%); cells growing under the flap (4.7%); and double vision (or "ghost images") in the operative eye (8.1%).
The following subjective symptoms were reported as present "often or always" by a higher percentage of subjects 3 months after treatment than before treatment: dryness (22% vs. 6%); halos (20% vs. 13%).
*Accutane® is a registered trademark of Hoffmann-La Roche Inc.
†Cordarone® is a registered trademark of Sanofi-Synthelabo, Inc.